Abstract:In England, and many other countries, immunity to SARS-CoV-2 infection and COVID-19 disease is highly heterogeneous. Immunity has been acquired through natural infection, primary and booster vaccination, while protection has been lost through waning immunity and viral mutation. During the height of the pandemic in England, the main aim was to rapidly protect the population and large supplies of vaccine were pre-purchased, eliminating the need for cost-effective calculations. As we move to an era where for the majority of the population SARS-CoV-2 infections cause relatively mild disease, and vaccine stocks need to be re-purchased, it is important we consider the cost-effectiveness and economic value of COVID-19 vaccination programmes. Here using data from 2023 and 2024 in England on COVID-19 hospital admissions, ICU admissions and deaths, coupled with bespoke health economic costs, we consider the willingness to pay threshold for COVID-19 vaccines in different age and risk groups. We partition the population into sixteen 5-year age-groups and three risk groups (no-risk, at-risk and immunosuppressed) and calculate the health savings, in terms of costs and quality adjusted life years (QALYs), per vaccine dose. We adopt three different methodological approaches to estimate the level of vaccine protection leading to five different estimates of efficacy. Willingness to pay thresholds vary from less than 1 GBP for younger age-groups without any risk factors, to over 100 GBP for older age-groups with comorbidities that place them at risk. This extreme non-linear dependence on age, means that despite the different method of estimating vaccine efficacy, there is considerable qualitative agreement on the willingness to pay threshold, and therefore which ages it is cost-effective to vaccinate. For pre-purchased vaccine, where the only cost is administration (≈10 GBP), a twice-yearly universal booster offer to all those aged 70 and over is cost-effective (the benefits outweigh the administration costs), while for the at-risk group this could be extended to those over 65. When the vaccine cost is included, the cost-effective ages reduce, such that at a total cost of 30GBP (for vaccine and administration) universal vaccine is only cost-effective for those over 75; while at 60GBP universal vaccine is only cost-effective for those over 80. The historic offer of COVID-19 vaccination to those 65 and over for the autumn 2023 programme and those over 75 for the spring 2023 programme, aligns with our cost-effective threshold for pre-purchased vaccine when the only cost was administration. However, for future programmes, when vaccine costs are included, the age-thresholds slowly increase thereby demonstrating the continued importance of protecting the eldest and most vulnerable in the population.

Too Few School Nurses to Administer Proposed Flu Vaccination Programme, Experts Say

UK Stands by Nasal Flu Vaccine for Children As US Doctors Are Told to Stop Using It

Barriers and facilitators of childhood flu vaccination: the views of parents in North East England

Barriers and facilitators to seasonal influenza vaccination uptake among nurses: A mixed methods study

Cost-effectiveness of routine COVID-19 adult vaccination programmes in England

Influenza Vaccination in Children Younger than 5 Years in the Region of Murcia (Spain), a Comparative Analysis among Vaccinating and Non-Vaccinating Parents: Data from the FLUTETRA Study

Sixty Seconds On: Flu Vaccination

Can uptake of childhood influenza immunisation through schools and GP practices be increased through behaviourally-informed invitation letters and reminders: two pragmatic randomized controlled trials

Cost-utility analysis of increasing uptake of universal seasonal quadrivalent influenza vaccine (QIV) in children aged 6 months and older in Germany

Head-to-head comparison of influenza vaccines in children: a systematic review and meta-analysis

Strategies to increase influenza vaccination rates: outcomes of a nationwide cross-sectional survey of UK general practice

Health and economic impact of seasonal influenza mass vaccination strategies in European settings: A mathematical modelling and cost-effectiveness analysis

Public health and economic benefits of seasonal influenza vaccination in risk groups in France, Italy, Spain and the UK: state of play and perspectives

Flu nudges ... and other research

Influenza and pneumococcal vaccination in the emergency department: is it feasible?

Systematic review and meta-analysis of indirect protection afforded by vaccinating children against seasonal influenza: implications for policy

Streptococcus pneumoniae: Nasal influenza vaccination, carriage density and transmission in families

An intercountry comparison of the impact of the paediatric live attenuated influenza vaccine (LAIV) programme across the UK and the Republic of Ireland (ROI), 2010 to 2017

Do we have enough evidence how seasonal influenza is transmitted and can be prevented in hospitals to implement a comprehensive policy?

Parental acceptability of vaccinating young children against influenza and COVID-19

A global review of seasonal influenza vaccine introduction: analysis of the WHO/UNICEF Joint Reporting Form